The program was recently extended to T2DM trials, although long-term studies will be fundamental to evaluate the risk-benefit ratio for this agent to be used as an alternative to the traditional SGLT2 inhibitors [47]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.